METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE
The present invention provides methods for amelioration of biomarkers associated with cardiovascular risk with (R)-2-amino-3-phenylpropyl carbamate (APC).
1 - 23 . (canceled)
24 . A method of ameliorating at least one biomarker of cardiovascular risk in a patient, the method comprising administering (R)-2-amino-3-phenylpropylcarbamate to the patient.
25 . The method of claim 24 , wherein the patient has a BMI of 25 kg/m 2 or greater.
26 . The method of claim 25 , wherein the patient has a BMI in the range from 25 kg/m 2 to less than 30 kg/m 2 .
27 . The method of claim 25 , wherein the patient has a BMI of 30 kg/m 2 or greater.
28 . The method of claim 24 , wherein the ameliorating at least one biomarker of cardiovascular risk comprises reducing blood pressure level of the patient.
29 . The method of claim 28 , wherein the reducing blood pressure level is reducing systolic blood pressure.
30 . The method of claim 28 , wherein the reducing blood pressure is reducing diastolic blood pressure.
31 . The method of claim 28 , wherein the reducing blood pressure is reducing both systolic blood pressure and diastolic blood pressure.
32 . The method of claim 28 , wherein blood pressure is reduced by 1 mm Hg or greater.
33 . The method of claim 28 , wherein blood pressure is reduced by 2 mm Hg or greater.
34 . The method of claim 24 , wherein the ameliorating at least one biomarker of cardiovascular risk comprises reducing triglycerides level of the patient.
35 . The method of claim 34 , wherein the ameliorating at least one biomarker of cardiovascular risk further comprises reducing body weight.
36 . The method of claim 35 , wherein body weight is reduced by 5% or greater.
37 . The method of claim 24 , wherein the ameliorating at least one biomarker of cardiovascular risk comprises reducing glucose level of the patient.
38 . The method of claim 37 , wherein the ameliorating at least one biomarker of cardiovascular risk further comprises reducing body weight.
39 . The method of claim 38 , wherein body weight is reduced by 5% or greater.
40 . The method of claim 24 , wherein the patient has been receiving (R)-2-amino-3-phenylpropylcarbamate for at least 40 weeks and has over that 40 weeks experienced at least about 5% loss in BMI as compared to before receiving (R)-2-amino-3-phenylpropylcarbamate.
41 . The method of claim 24 , wherein the patient has been receiving (R)-2-amino-3-phenylpropylcarbamate for at least 40 weeks and has over that 40 weeks experienced at least about 5% loss in body weight as compared to before receiving (R)-2-amino-3-phenylpropylcarbamate.
42 . The method of claim 24 , wherein the patient does not display an increased propensity toward a non-dipping classification over course of treatment.
43 . The method of claim 24 , wherein the patient receives about 75-150 mg/day of (R)-2-amino-3-phenylpropylcarbamate.
44 . The method of claim 43 , wherein the patient receives about 37.5, 75, 150, or 300 mg/day of (R)-2-amino-3-phenylpropylcarbamate.
45 . The method of claim 24 , wherein the patient receives 75 mg/day of (R)-2-amino-3-phenylpropylcarbamate for at least 3 days followed by 150 mg/day of (R)-2-amino-3-phenylpropylcarbamate.
46 . The method of claim 24 , wherein the patient does not have narcolepsy.